Shanghai Bao Pharmaceuticals' (HKG:2659) new drug application for KJ103 for injection was accepted by China's National Medical Products Administration and granted priority review status, according to a Thursday Hong Kong bourse filing.
The acceptance is for use of the drug for desensitization therapy in highly sensitized kidney transplant patients.